Regulatory Pathways
Applicable registration pathway per product category and country. Required submissions, technical file expectations, approval timelines, and local representative requirements — sourced from official regulator publications.
New: Manufacturing Quotes — source from manufacturers in 35 countries.Start a Project
Coverage
What GHMAP covers — and how
GHMAP structures market-access intelligence across 35 country markets. Every data point is sourced from official authorities, tagged with source type and review status, and reviewed by qualified professionals before it is used.
35
Countries with intelligence
35
Tier-1 full profiles
8
Intelligence types per market
7
Regions covered
What we cover
8 types of market intelligence per country
For each country in the GHMAP network, we structure intelligence across every dimension a healthcare manufacturer, distributor, or investor needs before committing to a market.
Reimbursement Structures
Public vs. private payer mix, DRG codes, HTA requirements, reimbursement pathway questions, and budget-impact expectations. Identifies where reimbursement is automatic, negotiated, or absent.
Payer Landscape
Who actually pays for healthcare products in each market — public health system, insurance, out-of-pocket, tender, or procurement. Identifies the decision-maker chain before any commercial commitment.
Distributor Readiness
Country-specific distributor qualification signals: required certifications, regulatory capability, hospital reach, and market coverage. Enables structured distributor search and evaluation.
KOL & Clinical Network
Key Opinion Leader identification per specialty and country. Clinical advisory context, institutional affiliations, and product review participation — structured for market-access advisory engagement.
Market Intelligence
Market size, growth rate, population data, competitive landscape signals, and launch complexity scores — organized per country and product category to support prioritization decisions.
Evidence Gaps
Local evidence expectations — what clinical or health economic evidence is required or expected for regulatory or reimbursement success in each market. Identifies gaps before submission.
Source Governance
Every data point is tagged with source type, publication date, and review status. Information from official regulators, government ministries, and payer authorities is distinguished from secondary or unverified sources.
Geographic coverage
35 countries across 7 regions
Tier-1 countries have full intelligence profiles. Tier-2 and Tier-3 countries have core regulatory and payer data with expanding depth. All profiles are actively maintained and reviewed.
Europe
CE marking pathways, HTA frameworks (G-BA, HAS, NICE), DRG structures, and national payer landscapes fully documented.
FranceGermanyItalyNetherlandsNorwayPolandRussiaSpainSwedenSwitzerlandTurkeyUnited Kingdom
Asia Pacific
PMDA, KFDA, CDSCO, TGA, NMPA pathways with market-size data, distributor landscapes, and KOL network intelligence.
ChinaIndiaIndonesiaJapanPakistanSouth KoreaThailand
Africa
Regulatory pathway, procurement, and distributor readiness intelligence for key African healthcare markets.
EgyptKenyaMaliNigeriaSouth Africa
Latin America
ANVISA, COFEPRIS, INVIMA pathways documented alongside distributor qualification requirements and public tender structures.
ArgentinaBrazilColombiaMexico
Middle East
SFDA, DHA, MOH approval pathways, GCC mutual recognition, and private-hospital procurement structures.
IsraelSaudi ArabiaUnited Arab Emirates
North America
FDA 510(k), PMA, De Novo, Health Canada pathways, CMS reimbursement codes, and payer landscape intelligence.
CanadaUnited States
Oceania
TGA approval pathways, Medicare Benefits Schedule context, and distributor landscape intelligence.
AustraliaNew Zealand
Source governance
Every data point has a source, a status, and a reviewer
GHMAP does not publish intelligence without verifying its source. Each record in the platform carries source type, publication date, and review status. No information is presented as verified until a qualified professional has reviewed it.
Source required
Data point identified but official source not yet attached
Source tracked
Official source attached, pending professional review
In review
Under active professional review by a qualified local reviewer
Reviewed
Confirmed by a qualified professional. Ready for business use.
To verify
Previously reviewed content flagged for re-verification
Outdated
Source confirmed outdated. Replacement sourcing underway.
Accepted source types
- →Official regulator publications (FDA, EMA, SFDA, ANVISA, PMDA, KFDA, TGA, Health Canada, NMPA, and others)
- →Government ministry healthcare documents
- →Payer and HTA authority guidelines (G-BA, NICE, HAS, AIFA, CVZ, and others)
- →Peer-reviewed literature where required to contextualize regulatory or reimbursement pathways
- →Qualified local professional review before any record is marked as verified
Reviewed launch planning
Use GHMAP to organize market-access decisions before committing launch resources.
GHMAP structures source status, evidence gaps, review needs, and next actions for market-access planning.
Professional review remains part of the workflow.